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Objectives: Depression is common in diabetes and linked to a wide range of adverse outcomes. UK policy indicates that depression should be treated using conventional psychological treatments in a
stepped care framework. This review aimed to identify current economic evidence of psychological treatments for depression among people with diabetes.
Method: Electronic search strategies (conducted in MEDLINE, EMBASE, PsycINFO, CINAHL, NHS EED) combined clinical and economic search terms to identify full economic evaluations of the relevant
interventions. Prespecified screening and inclusion criteria were used. Standardized data extraction and critical appraisal were conducted and the results summarized qualitatively.
Results: Excluding duplicates, 1,516 studies for co-morbid depression and diabetes were screened. Four economic evaluations were identified. The studies found that the interventions improved health
status, reduced depression and were cost-effective compared with usual care. The studies were all U.S.-based and evaluated collaborative care programs that included psychological therapies. Critical
appraisal indicated limitations with the study designs, analysis and results for all studies.
Conclusions: The review highlighted the paucity of evidence in this area. The four studies indicated the potential of interventions to reduce depression and be cost-effective compared with usual care.
Two studies reported costs per QALY gained of USD 267 to USD 4,317, whilst two studies reported the intervention dominated usual care, with net savings of USD 440 to USD 612 and net gains in
patient free days or QALYs.
Keywords: Cost-effectiveness, Systematic review, Diabetes, Depression
Major depression, a common disabling clinical condition, af-
fects 21/1000 (point prevalence) 16 to 65-year-olds in theUnited
Kingdom. The lifetime prevalence in individuals with diabetes
is 24 percent (1), three times higher than the general popula-
tion. Clinically relevant depression affects around 30 percent of
patients with diabetes and depression (2). People with diabetes
plus depression are less likely to be physically and socially ac-
tive, effectively communicate with healthcare practitioners or
comply with diet and treatment than people with diabetes alone.
These factors can lead to worse long term complications and
higher mortality (3;4). Problems with detection and treatment
of depression are compounded by long term conditions and
patients and healthcare professionals normalize symptoms of
depression and distress (5).
The NIHR funded Collaboration for Leadership in Applied Health Research and Care (CLAHRC) in
Greater Manchester, focuses on chronic vascular conditions. Within this program, the Practitioner
Theme is concerned with improving access and quality of care for people with co-morbid
depression and diabetes/CHD. The work reported in this paper was funded as part of this
program of work. Three of the authors (Jeeva, Bundy, and Davies) are also part of the
Manchester Academic Health Sciences Centre. Dickens is part of the University of Exeter and
Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC).
In theUK, depression is ordinarilymanaged in primary care.
UK government policy promotes increased access to mental
health care through commissioning and provision of health and
social care in primary care settings, supported by the Improving
Access to Psychological Therapies (IAPT) initiative and cross
governmental strategy to improve the balance between mental
and physical health care. Policy initiatives to improve access
to and quality of low-intensity interventions such as talking
therapies focused on innovations in service delivery in primary
care.
Management in primary care can support patients and prac-
titioners in avoiding talking about depression (5;6). This is rein-
forced by highly managed and time-limited GP consultations in
UK primary care (7). Mental health services are separated from
general practice, with poor access to psychological services,
hindering integrated, effective treatment (8).
Effective care for depression in patients with diabetes re-
quires changes in the attitudes, beliefs and behaviors of health-
care practitioners, with care models based on educational and
organizational changes in primary care (9). Collaborative care
models that include psychological interventions may be effec-
tive and cost effective in people with depression or long term
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conditions when healthcare systems are barriers to effective
treatments (10–12). Qualitative research and a systematic re-
view of psychological interventions to manage depression in
diabetes indicated the need for new approaches to overcome
the barriers to using evidence based interventions in long term
conditions (5;13).
However, decision makers need information about the rela-
tive costs, benefits and cost-effectiveness to inform policy and
practice changes to implement new interventions. This study
reports a focused systematic review of the cost-effectiveness
of psychological interventions in people with depression and
diabetes. The aims were to: (i) Identify and review current eco-
nomic evidence of interventions for people with diabetes and
co-morbid clinically relevant depression. (ii) Identify the level
of robustness or uncertainty of economic evidence about the
management of co-morbid depression (with diabetes). (iii) In-
form the design of prospective studies to support evidence based
policy and practice and identify key data to collect.
METHODS
Search Strategy
The search strategy (Supplementary Table 1, which
can be viewed online at http://dx.doi.org/10.1017/
S0266462313000445, shows the final search used in Medline)
combined economic search terms (14), with clinical terms from
a previous review (13) and validated by checking whether it
identified publications known to the research team. Electronic
searches were limited to January 2000 to May 2012. Older
studies may not reflect current service organization, provision
or funding which have changed substantially in recent years.
The search strategy was adapted for each of the electronic
databases searched, using the Ovid interface: Medline, Embase,
PsycINFO, CINAHL, and NHS Economic Evaluation Database
(NHS EED) databases.
Inclusion Criteria
Studies were included if they were published in English, re-
ported full economic evaluations with a synthesis of net costs
and outcomes in adults, compared two or more interventions to
manage depression in people with diabetes. Policy papers, cost
of treatment or burden of illness studies, letters, editorials, book
reviews and poster presentations were excluded.
Data extraction and Assessment
Two authors (FJ and LD) screened titles and abstracts and differ-
ences were resolved by discussion. Full papers were obtained
for titles and abstracts that met the inclusion criteria or were
uncertain. Full papers were assessed for inclusion in the review.
Data were extracted and critically assessed on a standardized
form by FJ and LD, using NHS EED guidelines (14) and de-
scriptively summarized using narrative tables.
RESULTS
Figure 1 summarizes the number of studies retrieved and
reasons for exclusion. Four economic evaluations along-
side or integrated with randomized controlled trials (RCT)
were included (15–18) and are summarized in Table 1 (and
Supplementary Table 2, which can be viewed online at
http://dx.doi.org/10.1017/S0266462313000445). None of the
four studies reported all the detail about participants and meth-
ods required for the summary tables or critical appraisal. Previ-
ously published reports of the evaluations were used to identify
this information.
Target Population and Participants
All studies were conducted in the United States and the target
population was people with major depression and diabetes (15–
17) and/or coronary heart disease (CHD) (18). In one study (15)
the target population was elderly people (60 years or more) with
major depression. For this study, a sub-group of participants
included in the original study (19) who also had diabetes were
analyzed.
In one study, the majority of participants were predomi-
nantly Hispanic people. The authors noted this group were at
higher risk of diabetes and co-morbid diabetes and depression
than non Hispanic white people (17). In one study 23 percent
to 30 percent of participants had coronary heart disease (CHD)
(18),whilst 82 percent to 89 percent had diabeteswith orwithout
CHD. This study did not present results separately for diabetes
and CHD. There appeared to be differences in demographic
characteristics between the usual care and intervention groups
in all but one of the studies (16–18).
Interventions
All studies evaluated collaborative care to help participants
manage depression in primary care. They included a care plan-
ning process of stepped depression management tailored to in-
dividual needs, care manager, psychological therapy and/or an-
tidepressant therapy. One study (18) actively targeted diabetes
(or CHD) in the care plans. Care managers delivered psycho-
logical therapy and were trained/specialist nurses, incorporated
into the primary care team. They were supervised by psychi-
atrists and/or primary care physicians to monitor progress and
adjust treatment plans according to treatment response. Care
managers contacted participants two to three times per month
initially to monitor and discuss progress.
Usual care was not described in any of the papers.
Costs and Outcomes
One study reported a cost-effectiveness analysis (16) whilst
cost-utility analyses were presented in the other three eval-
uations (15;17;18). All but one of the studies (17) used a
time horizon of 24 months (15;16;18), but costs and out-
comes were not discounted in any of the analyses. Three stud-
ies reported a payor perspective (16–18) and one reported a
societal viewpoint for the analyses (15;19). Tables 2 and 3
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4 studies included in 
qualitative synthesis 
Katon et al., 2006 
Simon et al., 2007 
Hay et al., 2012 
Katon et al., 2012 
6 full-text articles 
excluded 
Reasons for exclusion 
Not diabetes and 
depression = 4 
Not full economic 
evaluation = 2 
1,966 records identified from electronic database search  
Medline = 813, Embase = 811, PsycINFO = 39, CINAHL = 280, NHS EED 
= 23. Other sources were not searched.  
1516 records after duplicates removed 
1516 titles and abstracts screened  
1,506 records excluded 
Reasons for exclusion 
Not diabetes and 
depression = 1,341 
Not economic 
evaluation = 165  10 full-text articles 
assessed for eligibility 
0 studies included in 
quantitative synthesis 
(meta-analysis) 
Figure 1. Studies identified and retrieved published between 2000 and May 2012.
summarize the costs and outcomes. Costs are adjusted to a
single price year (USD 2011), using a medical care services in-
dex (20). Total costs of the intervention group were USD22,250
to USD29,100 over 24 months, whilst total costs of the com-
parator were USD21,900 to USD31,200 (15; 16; 18). One study
(17) did not report the total costs of care. The authors found no
statistically significant differences in the change in costs from
6 months prebaseline to the 18 month follow-up. On this basis
they assumed that the only cost attributable to the intervention
was the cost of providing the intervention so only included the
additional costs of the intervention with the costs of the com-
parator assigned as zero (17).
Three studies reported net savings (USD440-USD1206) for
the intervention (15;16;18). The 95 percent confidence intervals
(CIs) all cross zero, suggesting no statistically significant dif-
ference in costs between intervention and control groups. One
study reported a net cost (USD 548; 17).
Different measures were used to assess the impact of care.
Outcomes were reported for the intervention and control group
in two studies. These were depression free days (412 depression
free days, intervention vs. 359 depression free days control;
16) and QALYs (1.05 intervention vs. 0.92 control; 17). Three
studies reported net QALYs (0.063 to 0.335 QALYs gained),
and two studies reportedmonetarymeasures of net benefit (USD
1212 to USD 1520).
Table 3 reports the net costs, outcomes and incremental
cost-effectiveness ratio (ICER) of the interventions evaluated.
These indicate less variation in the data.
Critical Assessment
Risk of bias. Double blinding treatment providers and patients was
not feasible and all studies used blinded assessments, data entry
and analysis. Whether this was successful was not reported.
Individual participants were randomized, increasing risk
of contaminating practice and treatment between allocation
groups. Sample size estimates were reported for effectiveness,
not economicmeasures, and excluded cluster effects. Combined
with substantial variance in the economicmeasures, it is unclear
if sample sizes were sufficient to accurately estimate the ICER
and uncertainty.
One study did not adjust for imbalances in participant base-
line characteristics (15). Three studies did adjust for baseline
characteristics (16–18), but did not report a-priori identification
of characteristics that influence health status or costs. One study
included participants with CHD and no diabetes, but did not re-
port results separately (18). It is not reported whether there were
differences in the interventions’ cost-effectiveness or whether
people with depression and diabetes are comparable to those
with depression and CHD.
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Table 1. Study Designs for Evaluations of Interventions for Diabetes and Depression
Study (year) Katon et al. (2006) Simon et al. (2007) Hay et al. (2012) Katon et al. (2012)
Study participants Average age: 70 years Average age: 57–58 years Age: 69%–75%>= 50 years Average age: 56–57 years
Gender: 52%–54% female Gender: 34%–35% female Gender: 80%–85% female Gender: 48%–56% female
Ethnicity: 64%–65% white Ethnicity: 71%–80% white Ethnicity: 95%–97% white Ethnicity: 75%–78% white
Intervention and
comparator
Intervention: Stepped
collaborative care program,
including behavioral
activation plus problem
solving treatment or
enhanced anti-depressant
medication; n = 204
Intervention: Specialist nurse
delivered stepped care plan
for depression including
problem solving
psychotherapy or structured
anti-depressant
pharmacotherapy; n = 165
Intervention: structured stepped care
intervention including problem-solving
therapy and/or antidepressant medication,
monthly follow up, and care and service
systems navigation assistance; n = 193
Intervention: Collaborative care
management including nurse
care managers to develop
individual care plans and
provide behavioral interventions
plus usual care; n = 106
Comparator: Usual care (details
not provided); n = 214
Comparator: Usual care (details
not provided); n = 164
Comparator: Usual care plus educational
pamphlets and a community resource list;
n = 194
Comparator: Usual care plus
notification of participants
depression status (full details
not provided); n = 108
Source of effectiveness
data
Multi-center RCT in 18 primary
care clinics in five states in
USA
Multi-center RCT in 9 primary
care clinics
RCT in 2 community clinics in Los Angeles
County (1 primary care, 1 diabetes care)
Multi-center RCT in 14 primary
care clinics in Washington State
Source of resource use
and cost data
Detailed records of all patients
contacts
Resource use and cost derived
from administrative cost
records.
Resource use and cost derived from
administrative cost records for all patients
enrolled in trial
Resource use and cost derived
from administrative cost records
for all patients enrolled in trial
Resource use and costs not
reported separately
Resource use and costs not
reported separately
Resource use and costs not reported
separately.
Resource use and costs not
reported separately
Unit cost data not reported Unit cost data not reported Some unit costs reported. Medicare and
Federal Supply Schedule
Some unit costs reported, from
administrative data
Time horizon 24 months 24 months 18 months 24 months
Table 2. Total Costs (USD, 2011) and Patient Benefit
Mean cost Mean patient benefit
Intervention Control Intervention Control
Katon et al. (2006) 24 months time horizon
Mean: 25,250
95% CI: 22,328–28,174
Mean: 26,506
95% CI: 22,205–30,807
Benefit in the intervention group was not reported.
Incremental patient benefit reported in Table 3
Benefit in the control group was not reported.
Incremental patient benefit reported in Table 3
Simon et al. (2007) 24 months time horizon
Mean: 29,069
SD: 38,569
Mean: 31,163
SD: 49,853
Depression free days
Mean: 412
SD: 202
Depression free days
Mean: 359
SD: 207
Hay et al (2012) 18 months time horizon
Mean cost: 548
95% CI: 499–597
Mean cost: 0.00
95% CI: N.A.
QALYs
Mean: 1.05
QALYs
Mean: 0.92
Katon et al. (2012) 24 months time horizon (total outpatient costs only)
Mean: 22,255
95% CI: 18,255–26,258
Mean: 20,897
95% CI: 16,869–24,925
Benefit in the intervention group was not reported.
Incremental patient benefit reported in Table 3
Benefit in the control group was not reported.
Incremental patient benefit reported in Table 3
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Table 3. Net Costs (USD, 2011), Outcomes, and Incremental Cost-Effectiveness Ratios
Net cost of intervention, Net benefit of Probability of intervention
Authors USD, 2011 intervention ICER Net benefit being cost effective
Katon et al
2006
Net cost: −1,206
95% CI: -6,124–3,709
Net depression free days:
115.4
95% CI: 71.7–159.1
Net QALYS:
Lower estimate = 0.063
(95% CI 0.039–0.087)
Higher estimate = 0.126
(95% CI: 0.079–0.174)
Net cost/depression free day:
not reported
Net cost/QALY (outpatient
costs only):
Lower estimate = $267 (95%
CI:194–425)
Higher estimate = $534
(95% CI: 386–863)
Net benefit: $1,520
95% CI: 932–2,116 at
willingness to pay for
depression free day of $10
p = .67 that intervention
is cost saving and
effective
Simon et al.
2007
Net outpatient cost:−440
95% CI: −1,410–510
Net depression free days: 61
95% CI: 11–82
Not applicable, intervention
dominates
Net benefit: $440 if
willingness to pay for a
depression free day = $0
Net benefit: $1212 if
willingness to pay for a
depression free day = $10
Not reported
Hay et al
2012
Net cost: $548 Net QALYs: 0.13 Net cost/QALY: $4,317 Not reported p = .50 if decision
makers willing to pay
$5,000 to gain 1 QALY
p = .50 if decision
makers willing to pay
$12000 to gain 1 QALY
Katon et al
2012
Net outpatient cost:
Primary analysis:
$−612
95% CI: −3,523–2,115
Sensitivity analysis: $ −
1,149
95% CI: −3,881–1,582
Net depression free days: 114
95% CI: 79–149
Net QALYs: 0.335
95% CI: −0.18–0.85
Net cost/depression free day,
primary analysis: -$5.42
95% CI: −30.65–20
Net cost/depression free day,
sensitivity analysis: -$10.18
95% CI: −36.97–14.6
Net cost/QALY, primary
analysis: −$1,826
95% CI: −2,964–2,964
Net cost/QALY, sensitivity
analysis: −$ 3,396
95% CI: −4,134–2,804
Not reported p= .97 if decision makers
willing to pay $20,000
to gain 1 QALY
p= .50 if decision makers
willing to pay $12,000
to gain 1 QALY
Only two studies accounted for missing data (15;17). Insuf-
ficient information was reported to assess the assumptions used
and the robustness of the results.
Choice of Comparator. The comparator in all studies was usual care,
but what this comprised was not described. The relevance of
alternative comparators was not discussed. Differences in usual
care between studies may explain some of the variation in the
costs and outcomes reported.
Validity of Benefit and Cost Estimates. Three studies reported depression-
free days and net monetary values of depression-free days (pri-
mary analysis), which exclude adverse events or broader health
benefits of the intervention (15;16;18). Different willingness-
to-pay values to gain a depression-free day, were used, so are
not directly comparable.
One study used the SF-12 and SF-6D tariffs to estimate
QALYs (17). The SF-12 does not include all items for the SF-
6D, reducing the reliability and validity of the estimated results.
Two studies estimated QALYs by mapping published data onto
net depression-free days (15), or imputing from diabetes mark-
ers (18). This excludes adverse events, reduces the robustness
of the QALY estimate and reduces comparability with other
evaluations.
Direct nonmedical costs were not reported. Insufficient de-
tail was given to assess the impact of this on cost-effectiveness
estimates. Usual carewas not described, so it is not clearwhether
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the range of costs included is appropriate. Total costs in one
study only included outpatient costs (18). One study only re-
ported the net additional costs of the intervention (17) excluding
costs of other services to manage depression or diabetes. There
is insufficient information about the method of identifying and
attributing service use to assess the validity of this approach.
Length of follow-up ranged from 18–24 months. No study
extrapolated results over patient lifetimes, which is impor-
tant for diabetes and depression. All studies reported cost-
effectiveness acceptability analyses and/or net benefit analyses
but did not adequately report the methods or the relevance of
the range of willingness to pay thresholds used.
Transferability of Results. None of the studies used sensitivity analysis
to explore the transferability of the results to other settings
or countries. All studies were conducted in the United States,
and one person (Katon) was an author on all four. This may
indicate all studies were based in similar healthcare systems
and evaluated very similar interventions. If so, generalizability
of the intervention and results to other settings/countries, where
health care differs may be limited.
All studies were primary care based, using systematic
screening to identify eligible patients, which may not be feasi-
ble elsewhere. It may also change the service setting, affecting
the cost-effectiveness of the intervention. Information about
adherence with treatment protocols and therapeutic alliances
between healthcare professional and patients was not reported
and can influence the transferability of results between settings/
countries.
Whether the study samples were representative of the study
populations or other populations was unclear. Most participants
in one study (16) had Type 2 diabetes (96 percent). Whether
participants had Type 1 or Type 2 diabetes was not reported in
three studies. The proportion of patients who screened pos-
itive for depression and were randomized ranged from 19
percent to 74 percent. The reasons for this variation were
unclear.
No study reported unit costs, costs and resource use for all
cost items, limiting transferability between settings/countries.
DISCUSSION
Implications for Policy and Practice
This study reports a systematic review of full economic evalua-
tions of interventions to manage depression in people with dia-
betes. Four studies met inclusion criteria, indicating collabora-
tive care including psychological therapy may be cost-effective.
There were limitations with this review and the studies as-
sessed. This review was focused rather than comprehensive.
No hand searches or searches of the grey literature were con-
ducted, meaning key studies may have been missed. All the
studies included in the review evaluated models of collabora-
tive care. Collaborative care was not an objective of the review
and not explicitly included as a search term in the search strat-
egy. However, the search strategy did include terms relating to
psychological or behavioral interventions, which were key ele-
ments of the collaborative care approaches. Clinical experts in
the research team did not identify any additional evaluations that
were not identified in the electronic searches. The search strat-
egy did not explicitly include CHD as a search term, whereas 1
study included participants with depression and diabetes and/or
CHD. It is not possible to assess from this study whether the
results for the two groups are comparable.
Assessment of the internal validity and robustness of the
four studies was limited by the information reported about the
study design and methods. All the studies appeared to have
limitations in study design that increased the risk of selection
and measurement bias. Issues in the measurement of costs and
health benefit limit the validity of the estimates.
The generalizability of the results to other settings and coun-
tries may be limited. Key issues to consider are first, whether
the health systems and organization of care in the studies, (e.g.,
funding and patterns of service use) are typical of those found
in other parts of the United States or other countries. Second,
whether the intervention requires highly trained/specialist staff
to deliver it to achieve the same level of adherence, therapeutic
alliance and effectiveness, and the feasibility and acceptability
of this in other settings/countries. Third, whether the predomi-
nantly older participant samples are representative of the popu-
lations treated in other settings in terms of age, type of diabetes
(1 or 2) and main setting of care. A related point is whether
screening will be needed to identify patients and whether this
is feasible.
Implications for Research
The sample sizes reported may not be sufficient to accurately
represent the incremental cost-effectiveness of the intervention
or identify important differences in costs or health benefit. Ev-
idence from clinical research demonstrates that small studies
are associated with over-estimates of effects. Larger, well con-
trolled, prospective evaluations are needed to inform evidence
based policy and practice about cost-effectiveness. The evalu-
ations also need to take into account clustering effects where
experience from providing the intervention may influence the
type and quantity of care in the comparison group. The studies
reviewed provide information to estimate the sample sizes for
economic endpoints such as the net benefit statistic.
Work is needed to identify the relevant range of service use.
For example, costs of participant and family time (as inputs to
the production of care), purchase of care from private providers
and the costs of community and social care services are relevant
in some settings.
The measure of patient benefit in future evaluations should
reflect the impact of care on participants overall health.
This is particularly important if psychological therapies indi-
rectly affect adherence and the effectiveness of diabetes care.
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Qualitative and quantitative studies are needed to identify, from
the patient’s perspective, key attributes of health and estimate
the relative utility or value of these. The extent to which QALYs
and measures to estimate QALYs are relevant to these patient
groups should be explored (21).
Evaluations in broader samples of participants are needed.
The majority of participants in the studies were older, white
women. Screening and selection of participants means they are
not representative of all people with diabetes and depression.
Future evaluations require procedures to minimize the risk of
recruitment bias. Additionally, collecting demographic char-
acteristics of patients who do not participate could facilitate
analytic controls for this problem. For example, survey analy-
sis methods to weight participants’ data according to over and
under-represented characteristics may help to reduce the impact
of recruitment biases in the study sample.
Future evaluations should minimize missing observations
and data in participants who complete scheduled follow-up as
well as encourage complete follow-up. Where missing observa-
tions and censored data occur analytic approaches to impute the
missing data are required. These should be selected to minimize
biases and adequately represent uncertainty.
Economic models are needed to extrapolate the results to
other settings and populations, and longer time horizons as
well as provide the decision maker with the information re-
quired for evidence based policy and practice. This requires
more detailed reporting of the methods, assumptions and re-
sults of prospective evaluations to support formal synthesis of
economic evidence and development and analysis of economic
models.
CONCLUSION
A recent Cochrane review concluded that collaborative care is
an effective approach to themanagement of depression and anx-
iety (22) and there is evidence to support its use in managing
co-morbid depression and diabetes (23). Economic evidence
suggests that from a U.S. payers perspective, collaborative care
to manage depression in people with diabetes is associated with
gains in health benefit and may be cost saving. However, as dis-
cussed above, there are several issues that limit the relevance of
the results to alternative settings, timeframes, and populations.
These include differences in health systems and organization of
care between settings/countries, the feasibility and acceptabil-
ity of the intervention in other settings/countries, the selected
samples of participants may not be representative of routine
practice. Additionally, there is substantial uncertainty about the
robustness of the evidence. Variation in results in the studies
could reflect differences in: the perspective and range of costs
included; the availability and organization of care for long-term
conditions and depression between settings and populations; the
methods used to estimate costs and benefits; and the character-
istics of the study samples recruited.
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